NYSEAMERICAN:IGC IGC Pharma Q1 2026 Earnings Report $0.28 +0.00 (+0.46%) Closing price 09/25/2026 04:10 PM EasternExtended Trading$0.28 0.00 (-0.85%) As of 09/25/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IGC Pharma EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIGC Pharma Revenue ResultsActual Revenue$0.32 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIGC Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) IGC Pharma Earnings HeadlinesIGC Pharma (NYSEAMERICAN:IGC) Shares Up 3.3% - Still a Buy?September 23, 2026 | americanbankingnews.comIGC Pharma, Inc.: IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosureAugust 17, 2026 | finanznachrichten.deHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 27 at 1:00 AM | Stansberry Research (Ad)IGC Pharma, Inc.: IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutAugust 11, 2026 | finanznachrichten.deIGC Pharma Executives Convert Debt Into Equity SharesJuly 10, 2026 | theglobeandmail.comIGC Pharma, Inc.: IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative WorkflowJuly 9, 2026 | finanznachrichten.deSee More IGC Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email. Email Address About IGC PharmaIGC Pharma (NYSEAMERICAN:IGC) is a life sciences company focused on developing and commercializing cannabinoid-based therapies and other plant-derived pharmaceutical products. Its research and development efforts have included treatments for neurological and neurodegenerative conditions, including Alzheimer’s disease, as well as products intended to address pain, seizures and other health-related needs. The company has developed proprietary cannabinoid formulations and has pursued clinical development and regulatory advancement for its lead therapeutic candidates. It has also offered hemp- and cannabis-derived consumer products through its business operations, including products aimed at wellness and symptom management. IGC Pharma was formerly known as India Globalization Capital, Inc., a company that historically operated in infrastructure and technology-related businesses before shifting its primary focus toward cannabis and pharmaceutical activities. The company is based in the United States and has maintained international business connections. Ram Mukunda serves as its chief executive officer.View IGC Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
